Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) as Add-on Therapy in High Risk Hypercholesterolemic Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Mipomersen (Primary)
- Indications Coronary artery disease; Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- Sponsors Genzyme Corporation
- 20 Nov 2013 Pooled tolerability analysis assessing the incidence of cardiovascular events presented at the 86th Annual Scientific Sessions of the American Heart Association.
- 30 Aug 2013 Results published in the Journal of the American College of Cardiology.
- 06 Apr 2011 Efficacy and adverse events data presented at the 60th Annual Scientific Sessions of the American College of Cardiology (ACC-2011), according to a Genzyme and Isis Pharmaceuticals media release.